Thomas Foster Joins RNA Advisors as Managing Principal
![](https://rnaadvisors.com/wp-content/uploads/2024/01/Thomas-Foster-RNA-copy.jpg)
RNA Advisors, LLC, a leading valuation and strategic advisory firm focused exclusively on life sciences and healthcare technology, announced today that Thomas Foster has joined the firm as Managing Principal. Mr. Foster is a commercial expert and strategist who focuses on turning science into profitable revenue streams and corporate value. His work provides independent and […]
Client Success: Valuation Analysis for Revenue Cycle Healthcare Technology Spin-Out
![](https://rnaadvisors.com/wp-content/uploads/2016/08/Valuation_Advisory_1-1024x427.jpeg)
THE PROBLEM: Determine the fair market value of a spin-out of an existing successful healthcare technology company for purposes of tax and transaction planning purposes. THE SOLUTION: Financial modeling and diligence, transaction support and fair market value opinion. “You are our go to team for valuation support. You know your domain and are responsive.” – […]
Scott Winder joins RNA to expand its Life Science Tax and Financial Reporting Valuation Group
![](https://rnaadvisors.com/wp-content/uploads/2023/09/23_RNA_0821__2PD9624-1024x683.jpg)
RNA Advisors, LLC, a leading valuation and strategic advisory services firm focused exclusively in life sciences and healthcare technology, announced today that Scott Winder has joined the firm’s Valuation Advisory Services Group as a Managing Director. Based in the San Francisco Bay Area, Mr. Winder will work with RNA’s other senior officers to deliver a […]
Fairness Opinions: Why Expertise Matters Now More Than Ever in Life Sciences and Healthcare
![](https://rnaadvisors.com/wp-content/uploads/2023/01/Transactional_Support-1024x684.jpeg)
Since 2015, RNA Advisors has provided valuation, transactional and strategic advisory support services to over 300 life science and healthcare services clients encompassing over 1700 engagements, totaling over $282 billion in asset and transaction value. Our clients include top-tier venture-backed private companies, small to midsize public companies, private equity and VC investors, large health systems, […]
Client Success: Healthcare Transaction Support to Assess Value from Different Perspectives
![](https://rnaadvisors.com/wp-content/uploads/2022/04/robotarm_blog-1024x574.jpeg)
By Jeff Williamson THE SITUATION: A healthcare company with a portfolio of products in development for treating cardiac conditions was fielding investor interest for a potential acquisition. The company wanted to weigh the relative merits of raising additional equity financing versus exploring multiple M&A offers, as these initial discussions indicated a price range that did […]
Client Success: Mandatory Adoption of ASC 842 – Incremental Borrowing Rate Analysis for Private Biotech
![](https://rnaadvisors.com/wp-content/uploads/2022/04/Juggling_Rates_iStock-917475538-1-1024x562.jpeg)
By Jeff Suchocki, CFA The Situation: Adoption of ASC 842 – Lease Accounting is mandatory for all private companies for fiscal years beginning after December 15, 2021. To comply with this mandatory adoption requirement, a privately held, clinical stage biotech company needed to understand a reasonable discount rate for multiple lease agreements. The company requested […]
Client Success: Navigating Strategic Investment in Healthcare Technology
![](https://rnaadvisors.com/wp-content/uploads/2020/11/Medical-device-blog.jpeg)
THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The company received from the strategic partner a “low-ball” valuation. The company’s management team and board […]
Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech
![](https://rnaadvisors.com/wp-content/uploads/2019/07/The-Path-to-Commercialization-in-Life-Sciences-1024x615.jpg)
THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive […]
Why Valuation Matters in Early-Stage Life Sciences
![](https://rnaadvisors.com/wp-content/uploads/2021/07/iStock-909908830.jpg)
“Value”, the outcome of a thorough valuation analysis, is ultimately what parties agree to. Sometimes this seems a rational outcome, other times an irrational one. The reality is that a life sciences or healthcare technology company’s valuation often results from the ability or inability to create an effective bidding process and to persuade/anchor a strategic […]
Adaptive Valuation Approaches in Life Sciences and Healthcare
![](https://rnaadvisors.com/wp-content/uploads/2017/07/Home_page_healthcare_technology_consulting-1024x683.jpeg)
In finance, theories about the efficiency of markets have been both extraordinarily elegant and disastrously wrong on many occasions. These so-called efficient markets concepts have brought about interesting tools like the Capital Asset Pricing Model and Black-Scholes or Cox-Ross-Rubinstein binomial lattice models as tools for understanding how to assess a company’s cost of capital or […]